Wednesday, January 08, 2020 8:09:07 PM
Tomorrow morning in 2017 I was downstairs around 5am checking out the markets, any updates from Asia and Europe drinking coffee. Little did I know within the next cup of coffee Ariad would be halted pending news. I quickly did a twitter search and someone had posted Taketa buys Ariad $24. I never returned to that cup of coffee as I ran upstairs to tell my wife the news ...who had no idea why I was so excited at that time of the morning. I proceeded to tweet Adam Feuerstein, who had reviewed his 2016 bio hits and misses stating his Ariad call wasn't a hit or a miss cuz "It wasn't bought". and continuing to claim he was Right about slamming Ariad all year. I tweeted him that he may as well admit that he was Dead Wrong. He proceeded to retweet my tweet admitted Yes he was wrong. It was a fine day
Speaking of fielding offers from potential buyers, in the United States a target company isn't necessarily obligated to disclose any explorations of sale or negotiations prior to a binding agreement You can say the same on the other side where potential buyers have no duty to disclose in advance that they plan to buy someone. So in AUPH's case, we may never know if they have already fielded an array of offers and even debated accepting one around the Board table. In Ariad's case, Paris disclosed in SEC filings close to Feb 2017 that three offers were submitted by Taketa and the third was accepted on Dec 25 2016. Merry Christmas lol.
The only time a company must disclose the acquisition is after a binding agreement is sealed, a negotiation between both parties will directly cause a material event OR when a buyer first makes a toehold position and must file a schedule 13D if ownership is 5% or more...and refile after any material change like an ultimate takeout of remaining shares.
Speaking of fielding offers from potential buyers, in the United States a target company isn't necessarily obligated to disclose any explorations of sale or negotiations prior to a binding agreement You can say the same on the other side where potential buyers have no duty to disclose in advance that they plan to buy someone. So in AUPH's case, we may never know if they have already fielded an array of offers and even debated accepting one around the Board table. In Ariad's case, Paris disclosed in SEC filings close to Feb 2017 that three offers were submitted by Taketa and the third was accepted on Dec 25 2016. Merry Christmas lol.
The only time a company must disclose the acquisition is after a binding agreement is sealed, a negotiation between both parties will directly cause a material event OR when a buyer first makes a toehold position and must file a schedule 13D if ownership is 5% or more...and refile after any material change like an ultimate takeout of remaining shares.
Recent AUPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:05:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:04:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 09:03:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:07:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 01:20:50 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 05/11/2026 01:15:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 12:23:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:22:07 PM
- Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress • Business Wire • 05/07/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 08:31:08 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/13/2026 11:27:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/03/2026 08:56:49 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:19:18 PM
- Kezar Life Sciences shares surge after Aurinia announces acquisition • IH Market News • 03/30/2026 03:07:34 PM
- Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right • Business Wire • 03/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:03:47 PM
- Aurinia Announces Management Transition • Business Wire • 03/23/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:14:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 11:06:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 11:02:50 AM
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress • Business Wire • 02/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2026 09:08:05 PM
